Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial

Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial

Show other versions (1)

<p><strong>Background</p></strong> Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a proinflammatory cytokine overproduced in several inflammatory and autoimmune diseases, including axial spondyloarthritis. Namilumab is a human IgG1 monoclonal anti-GM-CSF antibod...

תיאור מלא

מידע ביבליוגרפי
Main Authors: Worth, C, Al-Mossawi, MH, MacDonald, J, Fisher, BA, Chan, A, Sengupta, R, Packham, J, Gaffney, K, Gullick, N, Cook, JA, Corn, TH, Teh, J, Machado, PM, Taylor, PC, Bowness, P
פורמט: Journal article
שפה:English
יצא לאור: Elsevier 2024

פריטים דומים